MELISSA SAULS: Open Payments
NPI 1063065050 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,897 in 194 payments from 13 companies in 2025. Trend: 2023 $3,451 · 2024 $4,977 · 2025 $3,897
Food & beverage: $3,897
| Company | Payments | Amount |
|---|---|---|
| QOL Medical, LLC | 16 | $520 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $495 |
| Janssen Biotech, Inc. | 21 | $397 |
| ABBVIE INC. | 17 | $389 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 43 | $363 |
| Celltrion USA Inc. | 18 | $276 |
| Lilly USA, LLC | 8 | $266 |
| GENZYME CORPORATION | 9 | $249 |
| Aimmune Therapeutics, Inc. | 13 | $228 |
| Ardelyx, Inc. | 10 | $208 |
Products named: Sucraid, TREMFYA, XIFAXAN, ENTYVIO, VEGZELMA, OMVOH, DUPIXENT, ZENPEP.
Industry payments across TX — which companies pay providers there.
